Canagliflozin Targeting Vascular Inflammation

This study is testing whether canagliflozin — a medication commonly used for type 2 diabetes and heart conditions — can reduce dangerous inflammation in the blood vessels of people who have both diabetes and stable coronary artery disease (heart disease caused by blocked arteries). **You may be eligible if:** - You have diabetes - You have stable coronary artery disease (at least 60 days after a heart attack) - You have given informed consent **You may NOT be eligible if:** - Your heart is pumping poorly (ejection fraction below 50%) - You have decompensated heart failure or active infection - You have an autoimmune condition (e.g., rheumatoid arthritis, lupus) or are on systemic anti-inflammatory therapy - You are pregnant, breastfeeding, or not using adequate contraception - Your kidney function is reduced (GFR below 50) - You are taking certain medications that interact with canagliflozin - You have liver disease Talk to your doctor to see if this trial is right for you.